Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in p…

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07421167

Phase 1

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia

The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the stud…

Immune Thrombocytopenia (ITP)

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06721013

Phase 2

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new d…

Immune Thrombocytopenia (ITP)

Estimated

~$10 – $8,750

Nuvig Therapeutics, Inc.NCT07095127

Phase 3

A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Adult Patients With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP

Chronic Primary Immune Thrombocytopenia (ITP)

Estimated

~$10 – $7,500

Kedrion S.p.A.NCT07059000

Phase 1

A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing a…

Immune Thrombocytopenia (ITP)Warm Autoimmune Hemolytic Anemia (WAIHA)

Estimated

~$10 – $8,750

Cullinan Therapeutics Inc.NCT07738822

Phase 1

Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a …

Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)+3 more

Estimated

~$10 – $8,750

Chugai PharmaceuticalNCT06371417

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). Af…

Primary Immune Thrombocytopenia (ITP)

Estimated

~$10 – $7,500

argenxNCT06544499